Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

被引：1
|
作者：
Bhutani, Manisha
House, Monika
He, Jiaxian
Atrash, Shebli
Foureau, David M.
Paul, Barry
Friend, Reed
Symanowski, James T.
Norek, Sarah
Begic, Xhevahire
Acampora, Donna
Farmer, Katherine K.
Syfert, Carrie Ann
Pineda-Roman, Mauricio
Voorhees, Peter
Usmani, Saad Z.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-138485
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial
    Landgren, Ola
    Hultcrantz, Malin
    Diamond, Benjamin
    Lesokhin, Alexander M.
    Mailankody, Sham
    Hassoun, Hani
    Tan, Carlyn
    Shah, Urvi A.
    Lu, Sydney X.
    Salcedo, Meghan
    Werner, Kelly
    Rispoli, Jenna
    Caple, Julia
    Sams, Allison
    Verducci, Dennis
    Jones, Katie
    Concepcion, Isabel
    Ciardello, Amanda
    Chansakul, Aisara
    Schlossman, Julia
    Tavitian, Elizabet
    Shekarkhand, Tala
    Harrison, Angela
    Piacentini, Casey
    Rustad, Even H.
    Yellapantula, Venkata
    Maclaughlan, Kylee
    Maura, Francesco
    Landau, Heather J.
    Scordo, Michael
    Chung, David J.
    Shah, Gunjan
    Lahoud, Oscar B.
    Thoren, Katie
    Murata, Kazunori
    Ramanathan, Lakshmi
    Arcila, Maria E.
    Ho, Caleb
    Roshal, Mikhail
    Dogan, Ahmet
    Derkach, Andriy
    Giralt, Sergio A.
    Korde, Neha
    [J]. JAMA ONCOLOGY, 2021, 7 (06) : 862 - 868
  • [42] Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone plus /- daratumumab induction regimen
    Meseha, Mina
    Abusamra, Murad
    Farooki, Azeez
    Derkach, Andriy
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Shah, Urvi
    Lu, Sydney
    Mailankody, Sham
    Patel, Dhwani
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Lesokhin, Alexander
    Korde, Neha
    Giralt, Sergio
    Usmani, Saad
    Tan, Carlyn
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S139 - S140
  • [43] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
    Hiroyuki Takamatsu
    Shinsuke Iida
    Hirohiko Shibayama 
    Kazuhiro Shibayama
    Hiroshi Yamazaki
    Kenshi Suzuki
    [J]. International Journal of Hematology, 2020, 111 : 692 - 701
  • [44] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
    Takamatsu, Hiroyuki
    Iida, Shinsuke
    Shibayama, Hirohiko
    Shibayama, Kazuhiro
    Yamazaki, Hiroshi
    Suzuki, Kenshi
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 692 - 701
  • [45] Isatuximab-carfilzomib-dexamethasone immediately after failing of the quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD): Striking response with no washout in a newly diagnosed multiple myeloma
    Gil-Fernandez, Juan Jose
    Ramirez, Patricia Garcia
    Charavia, Marta Callejas
    [J]. CLINICAL CASE REPORTS, 2024, 12 (01):
  • [46] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Korde, Neha
    Derkach, Andriy
    Hultcrantz, Malin
    Maclachlan, Kylee H.
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Lesokhin, Alexander
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Hofmeister, Craig C.
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Usmani, Saad Z.
    Lonial, Sagar
    Joseph, Nisha S.
    [J]. BLOOD, 2023, 142
  • [47] Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study
    Palumbo, Antonio
    Rossi, Davide
    Bringhen, Sara
    Larocca, Alessandra
    Gentilini, Fabiana
    De Paoli, Lorenzo
    Omede, Paola
    Ballanti, Stelvio
    Cavallo, Federica
    Passera, Roberto
    Liberati, Anna Marina
    Boccadoro, Mario
    Gaidano, Gianluca
    Sonneveld, Pieter
    Corradini, Paolo
    [J]. BLOOD, 2014, 124 (21)
  • [48] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM)
    Costa, Luciano
    Chhabra, Saurabh
    Medvedova, Eva
    Dholaria, Bhagirathbhai
    Schmidt, Timothy
    Silbermann, Rebecca
    Godby, Kelly
    Dhakal, Binod
    Bal, Susan
    Giri, Smith
    D'Souza, Anita
    Cornell, Robert
    Hardwick, Pamela
    Omel, James
    Hari, Parameswaran
    Callander, Natalie S.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S33 - S33
  • [49] Phase II trial of lenalidomide, cyclophosphamide, and dexamethasone (CRd) for newly diagnosed myeloma
    Kumar, Shaji
    Hayman, Suzanne R.
    Buadi, Francis K.
    Lacy, Martha Q.
    Stewart, Keith
    Greipp, Philip R.
    Russell, Stephen
    Zeldenrust, Steven
    Gertz, Morie A.
    Bergsagel, Leif
    Fonseca, Rafael
    Allred, Jacob
    Campbell, Megan
    Lust, John A.
    Witzig, Thomas E.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    [J]. BLOOD, 2007, 110 (11) : 64A - 64A
  • [50] Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma
    Kawano, Yawara
    Hata, Hiroyuki
    Takashio, Seiji
    Tsujita, Kenichi
    Ueda, Mitsuharu
    Matsuoka, Masao
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : E38 - E41
12345